Cardiovascular disease is the leading cause of death worldwide and atherosclerosis is the
underlying cause of cardiovascular events. In atherosclerosis, LDL is entrapped in the vessel …

… autoantibodies, antibodies to oxidized LDL (anti-oxLDL), the phospholipid cofactor β2GPI
(anti-β2GPI), anti-phosphorylcholine … [47] in acute coronary syndrome. These antibodies may …

… It has been demonstrated that the phosphocholine (PC) moiety … Cardiovascular outcomes
will be obtained over 6 years of … anti-OxLDL antibody ratios and pneumococcal antibody ratios …

… In this respect, the relevance of autoantibodies for CVD has been previously appreciated [42…
setting and expand the current knowledge on autoantibodies, namely anti-HDL antibodies, …

… consecutive patients (18–79 years of age) with acute coronary syndrome but without other
life threatening diseases from 1995 to 2001 (33). IgM anti-PC levels for 1185 patients were …

… in elderly patients [21,22]. Hence, we aimed to test whether cardiovascular and inflammation
… measured at hospital admission were associated with one-year mortality in elderly patients. …

… Increased CVD risk in … , autoantibodies and microparticles (MPs) have been implicated.
Women with SLE and previous adverse pregnancy outcomes (APO) are at increased risk of CVD. …

… monoclonal antibody (mAB) E06 which specifically recognizes the phosphocholine head …
Two mABs were utilized; the previously described mAB E06 recognizing phosphocholine …

… against apolipoprotein AI (ApoA-I) are associated with cardiovascular disease risks. We … -I
in coronary artery disease (CAD) and evaluate the potential risk of autoantibodies against their …

… [19–22] It was found that OxLDL antibody levels were better … outcome. CRP was reported
to bind to OxLDL [15] as part of the innate immune response to oxidized phosphorylcholine-…